Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics' stock has experienced positive topline data from THRIVE and THRIVE-2 trials, a BLA submission for veligrotug accepted by the FDA with Priority Review, and completed enrollment for REVEAL-1 and REVEAL-2 Phase 3 trials for VRDN-003. VRDN-006 showed proof-of-concept IgG reduction, and VRDN-008's IND submission is on track. The company completed financing transactions securing up to $889 million, resulting in a strong cash position. The stock maintains a "Strong Buy" rating with a significant price increase and upside potential.

As a clinical-stage biopharmaceutical company, Viridian Therapeutics does not generate revenue from commercialized products, so traditional product demand seasonality is not applicable. Revenue in 2025 was primarily from licensing agreements and collaboration payments, such as the $70 million upfront payment from Kissei Pharmaceutical. Financial performance is influenced by R&D spending, clinical trial progress, regulatory milestones, and capital raises.

Viridian Therapeutics operates in the Healthcare sector and Biotechnology industry, focusing on treatments for Thyroid Eye Disease (TED) and autoimmune diseases. Key product candidates include Veligrotug (VRDN-001), a humanized monoclonal antibody targeting IGF-1R, which has completed Phase 3 trials and has a BLA submitted to the FDA with potential launch in mid-2026. VRDN-003 (Elegrobart) is a next-generation IGF-1R monoclonal antibody in Phase 3 trials with topline data expected in Q1 and Q2 2026. VRDN-006 is a selective Fc fragment inhibiting FcRn, showing proof-of-concept IgG reduction in Phase 1. VRDN-008 is a bispecific, half-life extended FcRn inhibitor with an IND submission on track for year-end 2025.

Viridian Therapeutics is based in Waltham, Massachusetts, United States, and conducts global Phase 3 clinical trials. The company has an exclusive license agreement with Kissei Pharmaceutical for veligrotug and VRDN-003 in Japan.

Viridian Therapeutics has maintained a positive brand reputation due to promising clinical trial results and strong analyst support. The stock has a consensus "Strong Buy" rating. Positive data from the THRIVE and THRIVE-2 trials and accelerated timelines for VRDN-003 data have boosted investor confidence. The successful BLA submission for veligrotug and its Priority Review designation further enhance the company's reputation.

Viridian Therapeutics' ownership is concentrated among institutional investors. As of September 30, 2025, 368 institutional owners held approximately 93,843,133 shares. Major shareholders include Fmr Llc (Fidelity), BlackRock, Inc., Deep Track Capital, LP, Kynam Capital Management, LP, and Vanguard Group Inc. Institutional investors hold approximately 86.24% of the shares outstanding, while public/individual investors hold about 9.63%, and insiders hold 4.13%.